Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
In colorectal cancer (CRC), attempts to identify cancer cell-specific markers to guide antibody-mediated therapeutics have failed to uncover markers that are both exclusive to cancer tissues and abundant across CRCs. Alternatively, cancer-associated fibroblasts (CAFs), which are abundant in the tumor microenvironment and upregulate unique surface markers, are not found in healthy tissues. Here, we evaluated the expression patterns of CAF-associated proteins α-smooth muscle actin (αSMA), fibroblast activation protein (FAP), podoplanin (PDPN), matrix metalloproteinase-2 (MMP2), transgelin (TAGLN), and THY1. While αSMA and THY1 were abundant in cancer tissues, high abundance in normal tissues limited their targeting potential. FAP was present in 94.5% of primary and metastatic CRC tissues and absent in 93.7% of adjacent normal colon and liver tissues assessed. These results indicate that FAP is a promising target for antibody conjugates with potential for broad application in CRC. Co-expression analyses showed that CRCs simultaneously expressing high levels of PDPN, MMP2, and THY1 were enriched for immune-related signatures, indicating potential for antibody-mediated immune engagers. Overall, this work highlights the potential of CAF proteins to act as therapeutic targets for novel anticancer agents and become important therapeutic biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“in CRC, fibroblast activation protein was identified as a strong candidate for antibody conjugate therapy since it was found to be highly expressed in most CRC tissues and absent in >90% of adjacent normal tissues (colon and liver) [225].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [225]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 1×
“Base quality scores were calibrated using GATK [18] and mutations were called using Strelka v-2.”
MethodCerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“TCGA PanCancer Atlas COADREAD cohort data [22,23] were accessed via cbiopor-tal.org [24].”
MethodIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 2×
“TCGA PanCancer Atlas COADREAD cohort data [22,23] were accessed via cbiopor-tal.org [24].”
MethodCingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034 · cited 1×
“Heatmaps were built in R version 4.3.0 [26] using the package ComplexHeatmap version 2.16 [27,28].”
MethodInfluentialThe cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092 · cited 2×
“TCGA PanCancer Atlas COADREAD cohort data [22,23] were accessed via cbiopor-tal.org [24].”
MethodA framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863 · cited 2×
“Because of their role in immune regulation [5], CAFs may be important potential targets for these novel therapies.”
BackgroundThe Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update
Afgan, E., Baker, D., Batut, B., van den Beek, M., Bouvier, D., Čech, M., Chilton, J., Clements, D., Coraor, N., Grüning, B. A., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky379 · Cited by 3,662 · cited 1×
“These VCF files were uploaded to Galaxy at usegalaxy.org [21] and cross-referenced to ClinVar’s database via their downloadable VCF (accessed on 29 April 2019) for annotation of predicted clinical response.”
MethodÖzdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085 · cited 1×
“This study supports previous literature identifying FAP as a potential target in CRC [33–36].”
ResultOverman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · cited 2×
“…FAP expression and APC , BRAF , KRAS , PIK3CA , or TP53 mutation ( Χ 2 test: p = 0.749, 0.387, 0.097, 0.593, and 0.339, respectively; Figure Mismatch-repair (MMR) deficiency, a requirement for immunotherapeutic treatment and predictor of patient response in mCRC patients [30,31], was also assessed.”
BackgroundInfluentialGu, Z. (2022) · iMeta · doi:10.1002/imt2.43 · Cited by 1,885 · cited 1×
“Heatmaps were built in R version 4.3.0 [26] using the package ComplexHeatmap version 2.16 [27,28].”
MethodInfluentialColon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696 · cited 1×
“Current treatment options for non-resectable metastatic (m) CRC include cytotoxic chemotherapy, targeted therapies for cancers with specific molecular alterations, or immunotherapy for patients with mismatch-repair deficient (dMMR) cancers [2].”
BackgroundSelf-citationStrelka2: fast and accurate calling of germline and somatic variants
Kim, S., Scheffler, K., Halpern, A. L., Bekritsky, M. A., Noh, E., Källberg, M., Chen, X., Kim, Y., Beyter, D., Krusche, P., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0051-x · Cited by 1,632 · cited 1×
“8.4 [19] without matched controls and then annotated using SnpEff [20].”
MethodInfluentialSkewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads
Jiang, H., Lei, R., Ding, S.-W., & Zhu, S. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-182 · Cited by 1,521 · cited 1×
“Clean-up of reads was performed through quality trimming via Skewer [15] and alignment to Homo sapiens build 1k_v37 was performed using BWA-MEM [16].”
MethodLe, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02107 · Cited by 1,005 · cited 2×
“…FAP expression and APC , BRAF , KRAS , PIK3CA , or TP53 mutation ( Χ 2 test: p = 0.749, 0.387, 0.097, 0.593, and 0.339, respectively; Figure Mismatch-repair (MMR) deficiency, a requirement for immunotherapeutic treatment and predictor of patient response in mCRC patients [30,31], was also assessed.”
BackgroundInfluentialLineage-dependent gene expression programs influence the immune landscape of colorectal cancer
Lee, H.-O., Hong, Y., Etlioglu, H. E., Cho, Y. B., Pomella, V., Van den Bosch, B., Vanhecke, J., Verbandt, S., Hong, H., Min, J.-W., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0636-z · Cited by 910 · cited 1×
“The THY1 (CD90) cell surface antigen is often used as a pan-CAF marker, especially in CRC [6,7].”
BackgroundGarin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748 · cited 2×
“FAP is known to be expressed by stromal fibroblasts in the TME of many epithelial cancers [9,10].”
BackgroundIn search of definitions: Cancer‐associated fibroblasts and their markers
Nurmik, M., Ullmann, P., Rodriguez, F., Haan, S., & Letellier, E. (2020) · International Journal of Cancer · doi:10.1002/ijc.32193 · Cited by 739 · cited 3×
“The THY1 (CD90) cell surface antigen is often used as a pan-CAF marker, especially in CRC [6,7].”
BackgroundMethodScott, A. M., Wiseman, G., Welt, S., Adjei, A. A., Lee, F.-T., Hopkins, W., Divgi, C. R., Hanson, L. J., Mitchell, P., Gansen, D. N., et al. (2003) · PubMed · Cited by 438
Know thy neighbor: stromal cells can contribute oncogenic signals
Tlsty, T. D., & Hein, P. W. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00156-8 · Cited by 425 · cited 2×
“CAFs exhibit expression proteins rarely observed in normal tissues [8], making them a promising candidate for cancer-specific antibody-mediated therapies.”
BackgroundHofheinz, R.-D., al-Batran, S.-E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., Tanswell, P., Kunz, U., Amelsberg, A., Kuthan, H., et al. (2003) · Oncology Research and Treatment · doi:10.1159/000069863 · Cited by 374
Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer
Henry, L. R., Lee, H.-O., Lee, J. S., Klein-Szanto, A., Watts, P., Ross, E. A., Chen, W.-T., & Cheng, J. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1746 · Cited by 364 · cited 1×
“FAP expression has also been found to be associated with lower survival, especially in mCRC [32].”
BackgroundNew immune cell engagers for cancer immunotherapy
Fenis, A., Demaria, O., Gauthier, L., Vivier, E., & Narni-Mancinelli, E. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00982-7 · Cited by 203 · cited 2×
“Immune engagers most often refer to bi-specific antibodies that engage a tumor cell and a CD3+ T cell to facilitate T cell recognition [12–14].”
BackgroundJe, a versatile suite to handle multiplexed NGS libraries with unique molecular identifiers
Girardot, C., Scholtalbers, J., Sauer, S., Su, S.-Y., & Furlong, E. E. M. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1284-2 · Cited by 200 · cited 1×
“Deduplication was performed through Picard (https://picard.sourceforge.net; accessed on 3 September 2017) and Je [17].”
MethodFibroblast activation protein: A potential therapeutic target in cancer
Liu, R., Li, H., Liu, L., Yu, J., & Ren, X. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.3.18696 · Cited by 182
Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin
LeBeau, A. M., Brennen, W. N., Aggarwal, S., & Denmeade, S. R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1170 · Cited by 159 · cited 2×
“FAP is known to be expressed by stromal fibroblasts in the TME of many epithelial cancers [9,10].”
BackgroundSelf-citationFuchs, T. L., Sioson, L., Sheen, A., Nejad, K. J., Renaud, C. J., Andrici, J., Ahadi, M. S., Chou, A. S. Y., & Gill, A. J. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001409 · Cited by 136 · cited 2×
“Tissues were de fi ned as having high CD8 + T cell in fi ltration if they had greater than or equal to 5 CD8 + TILs The relationship between FAP score and CD8 + T cell infiltration is presented in Figure 3F. /HPF and low CD8 + T cell in fi ltration if they had fewer than 5 CD8 TILs/HPF [29].”
BackgroundFabre, M., Ferrer, C., Domínguez-Hormaetxe, S., Bockorny, B., Murias, L., Seifert, O., Eisler, S. A., Kontermann, R. E., Pfizenmaier, K., Lee, S. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2238 · Cited by 126 · cited 2×
“Fortunately, early preclinical work appears to support that such antibody–drug conjugates may more selectively kill cancer cells than slower-growing FAP + stromal cells [39].”
BackgroundRadioligands Targeting Fibroblast Activation Protein (FAP)
Lindner, T., Giesel, F. L., Kratochwil, C., & Serfling, S. E. (2021) · Cancers · doi:10.3390/cancers13225744 · Cited by 102 · cited 1×
“There are numerous ongoing clinical trials for the use of radiolabeled FAP-targeting antibodies as imaging agents, and a few studies are also exploring replacing radiolabeling with a radiotherapeutic agent [41,42].”
BackgroundCoto-Llerena, M., Ercan, C., Kancherla, V., Taha-Mehlitz, S., Eppenberger-Castori, S., Soysal, S. D., Ng, C. K. Y., Bolli, M., von Flüe, M., Nicolas, G. P., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00979 · Cited by 99 · cited 1×
“However, only collagen was associated with altered CD8 + T cell infiltration, despite previous RNA-based reports that FAP is associated with an immune suppressive environment [44] We next expanded our search to identify altered pathways in marker-high cancers.”
BackgroundCell Surface Markers in Colorectal Cancer Prognosis
Belov, L., Zhou, J., & Christopherson, R. I. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms12010078 · Cited by 81 · cited 1×
“Due to the heterogeneous nature of CRC and the development of these cancers from normal intestinal cells, identification of cell surface targets that can distinguish cancer cells from normal epithelial cells has proven to be a major challenge [3,4].”
BackgroundBridging the gap with multispecific immune cell engagers in cancer and infectious diseases
Rolin, C., Zimmer, J., & Seguin‐Devaux, C. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01176-4 · Cited by 77 · cited 2×
“Immune engagers most often refer to bi-specific antibodies that engage a tumor cell and a CD3+ T cell to facilitate T cell recognition [12–14].”
BackgroundTrispecific T-cell engagers for dual tumor-targeting of colorectal cancer
Tapia-Galisteo, A., Sánchez-Rodríguez, I., Aguilar-Sopeña, Ó., Harwood, S. L., Narbona, J., Ferreras-Gutiérrez, M., Navarro, R., Martín-García, L., Corbacho, C., Compte, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2034355 · Cited by 74
Yuan, Z., Hu, H., Zhu, Y., Zhang, W., Fang, Q., Qiao, T., Ma, T., Wang, M., Huang, R., Tang, Q., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03823-4 · Cited by 51 · cited 2×
“Additionally, FAP has been found to be expressed on some CRC cancer cells, adding to its potential as a cancer target [11].”
BackgroundSelf-citationRecent Clinical Implications of FAPI: Imaging and Therapy
Kiani, M., Jokar, S., Hassanzadeh, L., Behnammanesh, H., Bavi, O., Beiki, D., & Assadi, M. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005348 · Cited by 48 · cited 1×
“FAP-based imaging technologies are also being studied in cases of fibrosis, including in the lung [43].”
BackgroundAbbasian, M., Mousavi, E., Arab‐Bafrani, Z., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27619 · Cited by 38 · cited 1×
“Due to the heterogeneous nature of CRC and the development of these cancers from normal intestinal cells, identification of cell surface targets that can distinguish cancer cells from normal epithelial cells has proven to be a major challenge [3,4].”
BackgroundAn antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy
Xu, M., Chen, J., Zhang, P., Cai, J., Song, H., Zhu, L., & Liu, Z. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06300-6 · Cited by 36 · cited 1×
“There are numerous ongoing clinical trials for the use of radiolabeled FAP-targeting antibodies as imaging agents, and a few studies are also exploring replacing radiolabeling with a radiotherapeutic agent [41,42].”
BackgroundZana, A., Puig-Moreno, C., Bocci, M., Gilardoni, E., Nitto, C. D., Principi, L., Ravazza, D., Rotta, G., Prodi, E., Luca, R. D., et al. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00244 · Cited by 35 · cited 1×
“Preclinical studies have shown the feasibility of this method [39,40].”
Development of a Cross-Reactive Monoclonal Antibody for Detecting the Tumor Stroma
Hintz, H. M., Cowan, A. E., Shapovalova, M., & LeBeau, A. M. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00206 · Cited by 22
Self-citationGreimelmaier, K., Klopp, N., Mairinger, E., Wessolly, M., Borchert, S., Steinborn, J., Schmid, K. W., Wohlschlaeger, J., & Mairinger, F. D. (2023) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611163 · Cited by 15
Research works printed but not linked: 1
- Li H. Aligning Sequence Reads, Clone Sequences and Assembly Contigs with BWA-MEM arXiv 2013 1303.3997
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“For instance, in CRC, fibroblast activation protein was identified as a strong candidate for antibody conjugate therapy since it was found to be highly expressed in most CRC tissues and absent in >90% of adjacent normal tissues (colon and liver) [225].”
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
“By sustaining parallel pathways despite EGFR blockade, these stromal interactions highlight the importance of considering the tumor microenvironment as a therapeutic target [140,141].”
Zhang, Z., Tang, Y., Luo, D., Qiu, J. L., & Chen, L. (2025) · APL Bioengineering · doi:10.1063/5.0244706 · Cited by 27
Yin, Z., Zhou, Y., Zhu, X., Goettl, R. A., Wang, C., Weiss, H. L., Evers, B. M., & Wang, Q. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218060 · Cited by 20
Agostino, S. D., Padula, D. L., Rago, V., Gabriele, C., Conforti, F., Aprigliano, E., Urlandini, L., Parrotta, E. I., Lofaro, D., Vescio, F., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03496-3 · Cited by 14
“PDPN has previously been shown to mark CAF in the stroma surrounding the CRC [41, 42].”
Metadata
- Authors
- Shah, R., Johnson, K. A., Lippert, A. E. L., Kraus, S. G., Emmerich, P. B., Pasch, C. A., Zhang, W., Matkowskyj, K. A., LeBeau, A. M., & Deming, D. A.
- Affiliations
- University of Wisconsin–Madison (US)
- Corresponding author
- Deming, Dustin A.
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-09-14
- Volume
- 16
- Issue
- 18
- Pages
- 3158
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11440114
- OpenAlex
- W4402780081
- Cited by
- 18
- References
- 42
- Citations by year
- 2026: 4 · 2025: 14
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- JD Fluno Colorectal Cancer Precision Medicine Program (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
- ACI/Schwenn Family Professorship (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
- V Foundation (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
- NRSA (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
- NCI (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
- NIH/NCI (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
- 2018 Prostate Cancer Foundation Challenge Award (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
- Prostate Cancer Foundation Young Investigator Award (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- colorectal cancer, cancer-associated fibroblasts, fibroblast activation protein, therapeutic target, tumor microenvironment, alpha-smooth muscle actin, podoplanin, MMP-2, transgelin, CD90, antibody conjugates, immune-related gene signature, therapeutic biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.